Experimental study on long-term exposure to a biocompatible, hypertonic, pyruvate-buffered dialysis solution

Peritoneal Dialysis International

Volumn 28, Issue SUPPL. 5, 2008, Pages

  van Westrhenen, Roos ^a   Vlijm, Anniek ^a   Hiralall, Johan K ^a   Krediet, Raymond T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Amino acids; Glucose; Glycerol; Hypertonicity; Pyruvate

Indexed keywords

AMINO ACID; DIALYSIS FLUID; GLUCOSE; GLYCEROL; LACTIC ACID; PYRUVIC ACID; BUFFER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; EXPERIMENTAL STUDY; FIBROSIS; FILTER; FLUID TRANSPORT; LONG TERM CARE; MALE; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PRIORITY JOURNAL; RAT; ANIMAL; CHEMISTRY; DRUG ADMINISTRATION; DRUG EFFECT; PATHOLOGY; PERITONEUM; TIME; WISTAR RAT;

AMINO ACIDS; ANIMALS; BUFFERS; DIALYSIS SOLUTIONS; DRUG ADMINISTRATION SCHEDULE; GLUCOSE SOLUTION, HYPERTONIC; GLYCEROL; MALE; MODELS, ANIMAL; PERITONEAL DIALYSIS; PERITONEUM; PYRUVIC ACID; RATS; RATS, WISTAR; TIME FACTORS;

EID: 67149102486     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802805s09     Document Type: Article

References (25)

1. Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999; 55:341-56.
2. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
3. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
4. Hendriks PMEM, Ho-dac-Pannekeet MM, van Gulik TM, Struijk DG, Phoa SS, Sie L, et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport. Perit Dial Int 1997; 17:136-43.
5. Breborowicz A, Rodela H, Oreopoulos DG. Toxicity of osmotic solutes in human mesothelial cells in vitro. Kidney Int 1992; 41:1280-5.
6. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9:41-5.
7. Mateijsen MAM, van der Wal AC, Hendriks PMEM, Mulder JB, Struijk DG, Krediet RT. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19:517-25.
8. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
9. Williamson JR, Chang K, Rowold E, Marvel J, Tomlinson M, Sherman WR, et al. Sorbinil prevents diabetes-induced increases in vascular permeability but does not alter collagen cross-linking. Diabetes 1985; 34:703-5.
10. Krediet RT, van Westrhenen R, Zweers MM, Struijk DG. Clinical advantages of new peritoneal dialysis solutions. Nephrol Dial Int 2002; 17(Suppl 2):16-18.
11. Beyers-Mears A, Diecke FP, Mistry K, Ellison C, Cruz E. Effect of pyruvate on lens myo-inositol transport and polyol formation in diabetic cataract. Pharmacology 1997; 55: 78-86.
12. van Westrhenen R, Zweers MM, Kunne C, de Waart DR, van der Wal AC, Krediet RT. A pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a conventional solution. Perit Dial Int 2008; 28:487-96.
13. Matthys E, Dolkart R, Lameire N. Potential hazards of glycerol dialysate in diabetic CAPD patients. Perit Dial Int 1987; 7:16-19.
14. Zweers MM, Splint LJ, Krediet RT, Struijk DG. Effect of fluid supplementation and modality on peritoneal permeability characteristics in a rat peritoneal dialysis model. Perit Dial Int 2001; 21:58-64.
15. Pannekeet MM, Imholz AL, Struijk DG, Koomen GC, Langedijk MJ, Schouten N, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866-75.
16. Holmes CJ, Faict D. Peritoneal dialysis solution biocompatibility: definitions and evaluation strategies. Kidney Int Suppl 2003; 88:S50-6.
17. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factorin peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463:260-4.
18. Wieslander AP, Andren AHG, Nilsson-Thorell C, Muscalu N, Kjellstrand PTT, Rippe B. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 1995; 15:348-52.
19. Mahiout A, Brunkhorst R. Pyruvate anions neutralize peritoneal dialysis toxicity. Nephrol Dial Transplant 1995; 10: 391-4.
20. Shostak A, Gotloib L, Kushnier R, Wajsbrot V. Protective effect of pyruvate upon cultured mesothelial cells exposed to 2 mM hydrogen peroxide. Nephron 2000; 4:362-6.
21. Musi B, Carlsson O, Rippe A, Wieslander A, Rippe B. Effects of acidity, glucose-degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats. Perit Dial Int 1998; 18:303-10.
22. Albrektsson A, Bazargani F, Wieslander A, Braide A. Peritoneal dialysis fluid-induced angiogenesis in rat mesentery is increased by lactate in the presence or absence of glucose. ASAIO J 2006; 52:276-81.
23. Numata M, Nakayama M, Nimura S, Kawakami M, Lindholm B, Kawaguchi Y. Association between an increased peritoneal surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23: 116-22.
24. Krediet RT, van Esch S, Smit W, Michels WM, Zweers MM, Ho-dac-Pannekeet MM, et al. Peritoneal membrane failure in peritoneal dialysis patients. Blood Purif 2002; 20: 489-93.
25. Pietrzak I, Hirszel P, Shostak A, Welch PG, Lee RE, Maher JF. Splanchnic volume, not flow rate determines peritoneal permeability. ASAIO Trans 1989; 35:583-7.